Pioneer in leading-edge glucose monitoring systems selects clinivation WorldView as its most comprehensive, authoritative resource for building medical product submissions and registrations worldwide.
Framingham, MA, May 4, 2007 – clinivation, Inc. announced today that Abbott Diabetes Care, subsidiary of Abbott Laboratories (NYSE: ABT), has selected clinivation WorldView™.
“We are delighted that Abbott has selected clinivation WorldView as their most comprehensive, authoritative resource for regulatory intelligence,” remarked Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions. “Abbott will have unlimited, online access to clear explanations of the country-specific registration processes, and essential regulatory contacts, forms, and templates to achieve visibility on ever-changing regulations,” he continued.
Clinivation WorldView is your most comprehensive, authoritative, and up-to-date resource for building all of your medical device submissions and registrations worldwide. Clinivation WorldView also interoperates with clinivation Global® enterprise software to make building and tracking medical device submissions and registrations easier than ever before.
About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, California, is a worldwide leader in developing, manufacturing and marketing glucose monitoring systems designed to help patients better manage their diabetes. Abbott Diabetes Care is committed to developing products to reduce the discomfort and inconvenience of blood glucose monitoring and introducing systems that are easier to use, require smaller blood samples and provide faster results.
Abbott Diabetes Care has several leading-edge glucose monitoring systems and test strips in the United States for use in both home and hospital settings; leading brands include FreeStyle Lite™, FreeStyle Flash®, FreeStyle Freedom® and Precision Xtra™.
Additional information can be found at www.abbottdiabetescare.com.